Jessica is a Principal at F-Prime Capital and focuses primarily on the biopharmaceutical and medical technology sectors. Prior to joining F-Prime in 2015, Jessica was an engagement manager in McKinsey and Company’s Boston office, where she focused on pharmaceuticals and medical products and advised companies across a range of strategic, organizational, and operational topics. She began her career at MIT Lincoln Laboratory in the Biodefense Systems group, where she worked on developing novel techniques for the detection of biological agents.
Jessica holds a Ph.D. in genetics from Harvard University and received her BS in biology from Duke University, graduating summa cum laude.
Beam Therapeutics is pioneering the use of CRISPR base editing to develop precision genetic medicines that treat disease, one letter at a time. Learn more at www.beamtx.com.
Menlo Therapeutics Inc. (NASDAQ: MNLO) is a late stage biopharmaceutical company focused on the development and commercialization of serlopitant for the treatment of pruritus (itch) associated with dermatologic conditions such as atopic dermatitis, psoriasis and prurigo nodularis. Learn more at www.menlotherapeutics.com.
NFlection Therapeutics is a biopharmaceutical company focused on the development of therapies for Neurofibromatosis 1 (NF1), and other disorders. Learn more at www.nflectionrx.com.
Tempest Therapeutics is a development-stage biotechnology company advancing small molecule therapeutics that modulate anti-tumor immunity pathways. Learn more at www.tempesttx.com.